Virtu Financial LLC acquired a new stake in Aimmune Therapeutics Inc (NASDAQ:AIMT) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 6,316 shares of the biotechnology company’s stock, valued at approximately $239,000.
Other large investors have also recently made changes to their positions in the company. Daiwa SB Investments Ltd. grew its stake in shares of Aimmune Therapeutics by 44.5% during the fourth quarter. Daiwa SB Investments Ltd. now owns 7,290 shares of the biotechnology company’s stock worth $276,000 after buying an additional 2,245 shares during the last quarter. Teacher Retirement System of Texas bought a new stake in shares of Aimmune Therapeutics during the fourth quarter worth $282,000. SG Americas Securities LLC grew its stake in shares of Aimmune Therapeutics by 54.7% during the third quarter. SG Americas Securities LLC now owns 8,430 shares of the biotechnology company’s stock worth $209,000 after buying an additional 2,979 shares during the last quarter. Franklin Street Advisors Inc. NC grew its stake in shares of Aimmune Therapeutics by 43.8% during the fourth quarter. Franklin Street Advisors Inc. NC now owns 16,420 shares of the biotechnology company’s stock worth $621,000 after buying an additional 5,000 shares during the last quarter. Finally, American International Group Inc. grew its stake in shares of Aimmune Therapeutics by 8.1% during the third quarter. American International Group Inc. now owns 23,591 shares of the biotechnology company’s stock worth $585,000 after buying an additional 1,764 shares during the last quarter. 65.92% of the stock is currently owned by institutional investors and hedge funds.
Shares of Aimmune Therapeutics stock opened at $31.65 on Monday. Aimmune Therapeutics Inc has a one year low of $15.97 and a one year high of $42.00.
In related news, insider Mary M. Rozenman sold 1,807 shares of the business’s stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $33.10, for a total value of $59,811.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Douglas T. Sheehy sold 1,648 shares of the business’s stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $37.33, for a total transaction of $61,519.84. Following the completion of the sale, the insider now directly owns 1,648 shares in the company, valued at approximately $61,519.84. The disclosure for this sale can be found here. In the last three months, insiders purchased 58,093 shares of company stock worth $1,858,976 and sold 133,968 shares worth $5,073,180. Insiders own 17.59% of the company’s stock.
AIMT has been the topic of a number of research reports. Credit Suisse Group set a $45.00 target price on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a research note on Thursday, January 11th. Roth Capital boosted their target price on shares of Aimmune Therapeutics from $60.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Deutsche Bank set a $30.00 target price on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, February 20th. Zacks Investment Research raised shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 31st. Finally, Royal Bank of Canada initiated coverage on shares of Aimmune Therapeutics in a research note on Wednesday, February 7th. They set an “outperform” rating and a $55.00 target price on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. Aimmune Therapeutics has a consensus rating of “Buy” and an average price target of $57.22.
ILLEGAL ACTIVITY WARNING: “Virtu Financial LLC Acquires Shares of 6,316 Aimmune Therapeutics Inc (AIMT)” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://ledgergazette.com/2018/03/19/virtu-financial-llc-acquires-shares-of-6316-aimmune-therapeutics-inc-aimt.html.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Want to see what other hedge funds are holding AIMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aimmune Therapeutics Inc (NASDAQ:AIMT).
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.